E-stethoscope Developer Strados Labs Raises $1.93M From Private Stock Sale
Philadelphia medical device developer Strados Labs raised $1.93 million in a private stock sale.
Strados founder and CEO Nicholas Delmonico could not be reached for comment on the company’s plans for the funds.
The financing was disclosed in documents the company filed with the Securities and Exchange Commission.
In December, Strados received Food and Drug Administration marketing clearance for its flagship product called the RESP system, a lung sound monitor and connected platform.
The technology, also known as an e-stethoscope, enables doctors to identify abnormal breathing patterns remotely from anywhere and at any given time.
Read the full article here.